Skip to main content
. 2010 May;2(5):172–187. doi: 10.1002/emmm.201000072

Figure 2. Group V sPLA2 protects from K/BxN serum-transfer arthritis.

Figure 2

  1. Arthritis response in group V sPLA2 null and congenic control mice in a BALB/c group IIA null background. Mice were injected with 20 µl of K/BxN serum at days 0 and 2, and disease development was monitored for 13 days.
  2. Histomorphometric quantification of arthritis severity in group V sPLA2 null and congenic control mice at experimental day 13. N = 15 mice/group. Data are mean ± SEM pooled from three independent experiments. P < 0.001 for (A).
  3. Representative mid-saggital ankle sections from group V sPLA2 null and group V sPLA2 control mice. Upper and lower panels are 25× and 200× magnification, respectively (lower panel). White arrows demarcate the hyperplastic synovial lining surrounding a large effusion (upper) while black and white arrowheads highlight bone and cartilage erosions, respectively. Note the increased leukocytic infiltration, synovial lining hyperplasia and pannus formation in group V sPLA2 null mice (T, tibia; S, synovial space; C, calcaneus). Figures representative of findings in 15 mice/group.